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ABSTRACT
Purpose: All types of surgery are associated with complications. The debate is ongoing whether
robot-assisted radical prostatectomy can lower this risk compared to open surgery. The objective of
the present study was to evaluate post-operative adverse events leading to readmissions, using clinical
records to classify these adverse events systematically.
Materials and methods: A prospective controlled trial of men who underwent robot-assisted laparo-
scopic (RALP) or retropubic radical prostatectomy (RRP) at 14 departments of Urology (LAPPRO)
between 2008 and 2011. Data on all readmissions within 3 months of surgery were collected from the
Patient registry, Swedish Board of Health and Welfare. For each readmission the highest Clavien-Dindo
grade was listed.
Results: A total of 4003 patients were included in the LAPPRO trial and, after applying exclusion crite-
ria, 3706 patients remained for analyses. The results showed no statistically significant difference in
the overall readmission rates (8.1 vs. 7.1%) or readmission due to major complications (Clavien-Dindo
3b, 1.7 vs. 1.9%) between RALP and RRP within 90 days after surgery. Patients subjected to lymph-
node dissection (LND) had twice the risk for readmission as men not undergoing LND, irrespective
RALP or RRP technique. Blood transfusion was significantly more frequent during and within 30 days
of RRP surgery (16 vs. 4%). Abdominal symptoms were more common after RALP.
Conclusions: There is a substantial risk for hospital readmission after prostate-cancer surgery, regard-
less of technique; although major complications are rare. Regardless of surgical technique, attention
should be focused on specific types of complications.
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Robot-assisted laparoscopic radical prostatectomy (RALP) was
introduced and widely implemented without high-level evi-
dence of its superiority as compared to the retropubic radical
prostatectomy (RRP). A debate continues regarding the short-
and long-term pros and cons of RALP [1–3]. In the past, sur-
gical reports only listed complications of surgical procedures
that occurred during the index hospital stay and only listed
complications directly related to the surgical procedure. We
are now more aware that post-operative complications can
occur later; reports of complications within 90 days are now
common, including all adverse events as post-operative com-
plications. The classification system introduced by Clavien
and Dindo further improved the quality and comparability of
reporting complications and has been rapidly adopted by
the surgical community [4].
In LAPPRO (Laparoscopic Prostatectomy Robot Open), a
prospective comparative trial of two operative techniques of
radical prostatectomy, we have earlier presented patient-
reported adverse events within 3 months after the operation.
Using that data it was not possible to classify the events using
the Clavien-Dindo system. In order to explore serious
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post-operative adverse events leading to readmission, we
used medical records to classify these adverse events
systematically.
Method
This study took place within LAPPRO (Laparoscopic
Prostatectomy Robot Open); a prospective comparative trial
between RALP and RRP [5] using data from 14 Swedish
Urology departments in the years of 2008–2011 [6]. Seven
centres used the robot-assisted approach and seven centres
used the open approach. The inclusion criteria were age <75
years, the ability to read and write Swedish, informed consent,
tumour stage cT1, cT2, or cT3 (TNM Classification of Malignant
Tumors) [7] with no signs of distant metastases, and a pros-
tate-specific antigen level of <20ng/mL. Primary outcome was
Table 1. Clavien-Dindo classification.
Grades Definition
Grade I Any deviation from the normal post-operative course without the need for
pharmacological treatment or surgical, endoscopic, and radiological
interventions. Allowed therapeutic regimens are: drugs as antiemetics,
antipyretics, analgesics, diuretics, and electrolytes and physiotherapy.
This grade also includes wound infections opened at the bedside.
Grade II Requiring pharmacological treatment with drugs other than such allowed
for grade I complications. Blood transfusions and total parenteral
nutrition are also included.
Grade III Requiring surgical, endoscopic, or radiological intervention
- IIIa Intervention not under general anesthesia
- IIIb Intervention under general anesthesia
Grade IV Life-threatening complication (including CNS complications) requiring
I.C./I.C.U.-management
- IVa Single organ dysfunction (including dialysis)
- IVb Multi organ dysfunction
Grade V Death of a patient
brain hemorrhage, ischemic stroke, subarrachnoidal bleeding, but excluding transient ischemic attacks (TIA); IC,
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Start Date: September 1, 2008
End Date: October 7, 2011
Figure 1. Comparison between open and robot-assisted surgery concerning grade of Clavien-Dindo complications.
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post-operative adverse events leading to readmissions up to 3
months after surgery. Data on all readmissions within 3
months of surgery were collected from the Patient registry,
Swedish Board of Health and Welfare. These data made it pos-
sible to collect original documentation for all readmissions.
For each readmission only the highest Clavien-Dindo grade
was listed, even if several complications had occurred (Table
1). A quality control of grading was made by external
reviewers. Data on blood transfusions within 30 days of sur-
gery were retrieved from the Departments of Transfusion
medicine of the participating hospitals. Hence, transfusions
given during index admission were included. Causes for
readmission defined by ICD-10 codes were grouped into
seven groups, presented in Figure 1 (Table 2). The Regional
Ethical Review Board in Gothenburg (No 277-07) approved the
study. The trial is registered in the Current Controlled Trials
database (ISRCTN06393679).
Statistics
The pre-defined statistical analysis plan can be found in the
Supplementary Appendix. The percentage of patients with
one or more re-admissions within 3 months was analyzed
with the modified Poisson regression approach of Zou [8].
The number of readmissions was analyzed with negative
binomial regression. Covariates used for adjustments con-
cerning readmissions were those used in the previously pub-
lished analysis of patient-reported complications with the
addition of type of residence (urban/rural) [9]. For the two
secondary variables, the percentage of patients with Clavien-
Dindo classifications 3b or higher and the percentage of
patients given a transfusion, the modified Poisson regression
was used. Age at surgery, prostate weight, and residence
were used as covariates in the statistical model. Results are
presented as ratios (RALP vs. RRP), 95% confidence intervals,
and p-values. No correction for multiplicity was performed.
Multiple imputation by chained equations was used to han-
dle missing values in the different covariates used for adjust-
ment in the analyses [10]. Statistical analyses were
performed using SAS vs. 9.4 (SAS Institute Inc., Cary, NC).
Results
In total 4003 patients were included in the LAPPRO trial.
Applying exclusion criteria, 3706 patients remained for analy-
ses, where 2764 men were operated on by RALP and 942 by
Table 2. Causes for readmission defined by ICD-10 codes.
Urinary tract complications N133, N310, N320, N359, N459, N991, R319, R339, R349, R390, T830, T838
Abdominal complications I890, I898, K403, K409, K430, K450, K560, K566, K567, K573, K579, K590, K650,
K920, K922, L028, R103, R104, T797, T812, T813
Pulmonary embolism I269
Cardiovascular complications I109, I200, I211, I214, I213, I330, I469, I471, I479, I489, I639, I959, I978, R074
Bleeding complications D629, D649, T810
Infectious complications A099, A415, A419, B999, B954, I889, J189, K613, N109, N309, N390, N412,
R509, T814
Miscellaneous C181, C649, D709, E876, E835, F103, F323, G545, J340, J690, J909, K209, K210,
K862, M161, M459, M543, M751, M796, N185, N201, R060, R119, R252, R410,
R519, R529, R799 , S321, T140, T796, T818, T819, T888, T889, Y836, Y881, Z038,
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Figure 2. Flow chart.
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RRP (Figure 1). Men operated on by the robot-assisted pro-
cedure had higher clinical tumour stages, but lower pre-
operative PSA levels. Limited lymph node dissection was sig-
nificantly more common during open procedures, whereas
extended lymph node dissection was more common in the
robot-assisted group (Tables 3 and 4).
There was no statistically significant difference in readmis-
sion rates or in major complications defined as Clavien-
Dindo 3b or higher between the surgical techniques,
RR¼ 1.16 (95% C.I.¼ 0.88–1.53) and RR¼ 0.91 (95%
C.I.¼ 0.52–1.58), respectively (Table 5). Furthermore, there
was no statistically significant difference in men operated on
by experienced surgeons, defined as having performed 100
operations or more, or the sub-groups of men who under-
went lymph-node dissection (LND), regarding readmission
rates and major complications. However, in a sub-group ana-
lysis patients undergoing LND, regardless of operative tech-
nique, had a statistically significant higher risk for
readmission according to the adjusted analysis (14 vs. 7%,
p-value <0.001).
Patients in the RRP group received significantly more
blood transfusions than patients in the RALP group (4 vs.
16%, RR 0.25 (95% C.I.¼ 0.20–0.33)) during surgery and until
30 days after surgery (Table 5). RALP was more often associ-
ated with grade 1 complications, which corresponds to any
deviation from the normal post-operative course without the
Table 3. Baseline characteristics of the patientsa.
Variable RR.b RALPc p-value
No. Evaluated patients (%) 942 (25%) 2764 (75%)
Median age at surgery (Range) 63 (42–77) 63 (37–79) 0.0805
(quartiles) (59–67) (59–67)
Missing information N/A & N/A
Clinical stage no. (%)
T1 579 (65) 1592 (59) 0.0004
T2 277 (31) 1026 (38)
T3 38 (4) 82 (3)
Missing information 48 & 64
Gleason score preop. no. (%)
6 468 (51) 1377 (50) 0.0757
3þ 4 288 (31) 945 (34)
4þ 3 109 (12) 253 (9)
8 58 (6) 173 (6)
Missing information 16 & 19
Prostate weight preop. no. (%)
(g)
0–20 34 (4) 138 (5) 0.0139
20–40 480 (56) 1425 (57)
40–60 227 (26) 694 (28)
60–80 83 (10) 193 (8)
>80 39 (5) 70 (3)
Missing information 79 & 244
Median PSA (range)d 6.6 (0.59–99) 6.1 (0.09–176) 0.0006
(quartiles) (4.6–10) (4.5–9)
Missing information 19 & 9
Median mm cancer in biopsies, n (range) 7.2 (0.1–166) 8 (0.1–166) 0.3258
(quartiles) (3.5–16) (4–16)
Missing information 121 & 165
Median of proportion of positive biopsies, n (range) 0.3 (0–1) 0.3 (0–1) 0.1626
(quartiles) (0.2–0.5) (0.2–0.5)
Missing information 58 & 120
ASA classification, n (%)
1 598 (66) 1708 (63) 0.1667
2 283 (31) 943 (35)
3 20 (2) 55 (2)
Missing information 41 & 58
Educational level
(years in school)
University/college (>13) 279 (34) 957 (39) 0.0845
Technical training school (12–13) 95 (12) 296 (12)
High school (10–12) 251 (31) 705 (73)
Elementary school (9) 168 (21) 433 (18)
Other 14 (2) 41 (2)
Missing information 138 & 332
Lymph node dissection, n (%)
Extended 80 (8) 259 (9) <0.0001
Limited 197 (22) 92 (3)
Not done 639 (70) 2395 (88)
Missing information 26 & 18
aBecause of rounding, percentages may not total 100.
bRetro pubic radical prostatectomy.
cRobot assisted laparoscopic radical prostatectomy.
dProstate specific antigen, ng/ml.
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need for pharmacological treatment or surgical, endoscopic,
and radiological interventions, while RRP was more often
associated with grade 2 complications, which corresponds to,
for example, blood transfusions and antibiotics (Table 6). In
the RALP group, readmissions due to abdominal symptoms
were significantly more common, while disorders of lymph-
atic vessels and lymph nodes leading to readmission were
significantly more common in the RRP group (Table 7). There
was no statistically significant difference in rates of pulmon-
ary embolism between the surgical groups.
Discussion
In this prospective comparative trial based on inpatient regis-
try data we found no statistically significant difference in re-
admittance rates between RRP and RALP or the rate of major
complications defined as Clavien-Dindo 3b or higher. These
results are consistent with our previously published paper
based on patient reports [11]. However, the reasons for re-
admittance differed between the two techniques. In the
robotic group, abdominal symptoms were more common,
while blood transfusions were more common in the
RRP group.
Leow et al. [12] could, in a registry based study based on
inpatient data from 629,593 patients operated on in 449 hos-
pitals in the US between 2003 and 2013, show no difference
in major complications (Clavien-Dindo 3) between RRP and
RALP In that study minor complications not requiring inter-
vention (Clavien-Dindo <3) were slightly more common and,
in the RRP group and also in correlation with our material,
the number of patients receiving a blood transfusion were
higher in the RRP group. Similarly, the randomized controlled
trial by Yaxley et al. [13] could not find any statistically sig-
nificant difference between the two surgical approaches with
308 assessable patients.
Transfusion rates of 16% in RRP cases were higher than in
the reports by Trinh et al. [14] from a nationwide inpatient
sample from high volume centres in the U.S.A. reporting 8%
of blood transfusions. However, Alemozaffar et al. [15]
reported transfusion rates as high as 30% in RRP cases from
the Health Professionals Follow-up Study. The present study
included both high and low volume centres, which could in
part explain the relatively high rate of transfusions.
Additionally, differences between centres might be explained
by arbitrary and person-dependent transfusion limits. Blood
transfusion is a grade 2 complication according to the
Clavien-Dindo classification and as such is often downplayed
Table 4. Post-operative tumour characteristics and prostate weighta.
Variable RRPb RALPc p-value
pT stage, n (%)
pT2 651 (71) 1935 (71) 0.0445
pT3 252 (27) 753 (27)
pT4 11 (1) 12 (0.5)
pTX 1 (0.1) 26 (1)
Missing information 27 & 38
Gleason score postop. n (%)
6 341 (37) 954 (35) 0.3510
3þ 4 354 (38) 1131 (41)
4þ 3 161 (17) 437 (16)
8 69 (8) 209 (8)
Missing information 17 & 33
Prostate weight postop. n (%)
(g)
0–20 4 (0.5) 22 (1) 0.001
20–40 315 (34) 1113 (41)
40–60 405 (44) 1143 (42)
60–80 124 (14) 319 (12)
>80 67 (7) 134 (5)
Missing information 27 & 33
aBecause of rounding, percentages may not total 100.
bRetro pubic radical prostatectomy.
cRobot assisted laparoscopic radical prostatectomy.





n (%) Unadj RR (95% CI) Adj RRc (95% CI) p-value
Readmissions overalld
All patients 68 (7.1) 221 (8.1) 1.11 (0.85–1.44) 1.16 (0.88–1.53) 0.285
operated on by experienced surgeons 57 (7.1) 151 (8.2) 1.15 (0.86–1.55) 1.21 (0.89–1.65) 0.233
operated on with lymph-node dissection 35 (12.5) 57 (15.7) 1.26 (0.85–1.86) 1.30 (0.85–1.99) 0.225
No of readmissions
0 873 (93) 2544 (92) 1.06 (0.79–1.39) 1.10 (0.83–1.46) 0.504
1 55 (6) 186 (7)
2 9 (1.1) 30 (1.1)
3 4 (0.4) 5 (0.2)
Clavien Dindo 3b or moree
All patients 18 (1.90) 46 (1.70) 0.87 (0.51–1.49) 0.91 (0.52–1.58) 0.733
operated on by experienced surgeons 15 (1.9) 36 (2.0) 1.05 (0.58–1.90) 1.12 (0.61–2.07) 0.713
operated on with lymph-node dissection 4 (1.4) 10 (2.8) 1.93 (0.62–6.09) 1.93 (0.61–6.17) 0.266
Transfusionsf
All patients 154 (16) 112 (4) 0.25 (0.20–0.31) 0.25 (0.20–0.33) <0.001
operated on by experienced surgeons 126 (15.7) 76 (4.1) 0.26 (0.20–0.35) 0.27 (0.20–0.36) <0.001
operated on with lymph-node dissection 47 (16.7) 12 (3.3) 0.20 (0.11–0.36) 0.20 (0.10–0.37) <0.001
aRetro pubic radical prostatectomy.
bRobot assisted laparoscopic radical prostatectomy.
cAdjusted for employment, International Prostate Symptom Score (IPSS), neurologic disease, mental disorder, kidney disease, pros-
tate weight, and residence.
dPatients with one or more re-admissions within 3 months.
eAt least one Clavein-Dindo complication of grade 3b or higher.
fPatients with at least one unit of transfusion or more within 1 months from index surgery.
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in the academic literature, as a minor adverse event. For pros-
tate cancer patients during or after radical prostatectomy, the
effect of transfusion remains a matter of debate. It is debated
whether transfusion could be a negative prognostic factor,
leading to earlier cancer recurrence or shorter overall survival
[16–23]. However, the evidence is still conflicting regarding
this matter. It is postulated that transfusion has an immuno-
suppressing action, leading to less tolerance in infections and
cancerous development. Another argument is related to the
increased intraoperative blood loss, which obscures the opera-
tive field, causing a less accurate excision of the tumour and
positive surgical margins. In that sense, our study concurs
with the available literature that RALP is advantageous com-
pared to RRP, in terms of blood transfusion, which is expected
since RALP is a minimally invasive procedure.
In line with our previous patient reported results, lymph-
node dissection generally increased the risk of complications
for both RRP and RALP [11]. Keskin et al. [24] could, in a
study of 521 consecutive patients undergoing RALP and
LND, report that 9% of all patients developed a lymphocele
detectable by ultrasonography and 2.5% developed symp-
tomatic lymphoceles. In another study of 79 consecutive
patients followed after RALP and LND, Orvieto et al. reported
that as many as 51% developed a lymphocele detectable on
ultrasonography, and over 15% developed clinical symptoms
[25]. A substantial percentage of lymphoceles require inter-
vention, in most cases percutaneous drainage in local
anesthetics and, thus, having a Clavien-Dindo classification of
3a. In our study, virtually all lymph node dissections in the
RALP group were extended, while most in the RRP group
were limited. It is likely that more extensive dissection of
lymph nodes carries a higher likelihood of post-operative
lymphocele and, thus, results in a higher rate of intervention
classified as Clavien-Dindo 3a. The trans-abdominal approach
of the RALP procedure will also presumably lead to lymph
leaking into the abdominal cavity and, thereby, cause more
symptoms than extra-peritoneal leakage would.
In contrast to our finding using patients’ reports, where we
found a higher risk of thromboembolic complications after
RRP [11], we found no statistically significant difference in
occurrence of pulmonary embolism leading to hospital admit-
tance between the surgical groups. Furthermore, there were
no readmittances due to deep venous thrombosis (DVT.) alone
in this material. A likely explanation of this difference in out-
come is that, in Sweden, patients with DVT would mainly be
treated as outpatients. Two large studies in the early 2000s by
Lapidus et al. [26] and B€ackman et al. [27] could establish that
outpatient treatment of DVT was both safe and cost-effective.
The consequence is that today more than 80% of all patients
with DVT are treated as outpatients in Sweden and, as
patients undergoing radical prostatectomy should have a long
life expectancy to benefit from the procedure, it is likely that
they are more fit than the general population developing DVT
and thereby have a higher rate of outpatient treatment.
However, a previous report by Van Hemelrijck et al. [28] evalu-
ating a large population-based cohort, using data from the
Prostate Cancer Database Sweden (PCBaSe), showed that sur-
gery for prostate cancer was associated with hospitalization
for thromboembolic diseases.
In our previous published paper based on patient-
reported outcomes, we reported that RALP and RRP had
comparable and not statistically significant different rates of
90-day readmissions (9.3% vs. 7.7%) [9]. These numbers are
comparable to a study from the population based, nation-
wide PCBaSe (Prostate Cancer data Base Sweden) reporting
9% vs. 10% 90-day readmission rates after robot-assisted and
Table 7. Frequency table over complications causing readmissions after RRP vs. RALP
Total RRP RALP







1 T814 Infection following a procedure, not elsewhere classified 25 (0.67) 5 (0.53) 20 (0.72) 0.8076
2 T810 Hemorrhage and hematoma complicating a procedure, not elsewhere classified 21 (0.57) 4 (0.42) 17 (0.62) 0.7916
3 T818 Other complications of procedures, not elsewhere classified 21 (0.57) 3 (0.32) 18 (0.65) 0.4252
4 N390 Urinary tract infection, site not specified 15 (0.4) 4 (0.42) 11 (0.4) 0.7580
5 R104 Other and unspecified abdominal pain 15 (0.4) 0 (0.0) 15 (0.54) 0.0259
6 R319 Unspecified hematuria 14 (0.38) 5 (0.53) 9 (0.33) 0.3300
7 I269 Pulmonary embolism without mention of acute or pulmonale 12 (0.32) 4 (0.42) 8 (0.29) 0.4857
8 R339 Retention of urine 11 (0.3) 5 (0.53) 6 (0.22) 0.1375
9 I489 Atrial fibrillation and atrial flutter, unspecified 10 (0.27) 2 (0.21) 8 (0.29) 1.0000
10 I898 Other specified non-infective disorders of lymphatic vessels and lymph nodes 9 (0.24) 7 (0.74) 2 (0.07) 0.0007
11 Y881 Sequelae of misadventures to patients during surgical and medical procedures 8 (0.22) 4 (0.42) 4 (0.14) 0.0915
12 A415, A419 Sepsis 7 (0.19) 2 (0.21) 5 (0.18) 0.6691
13 T812 Accidental puncture and laceration during a procedure, not elsewhere classified 6 (0.16) 2 (0.21) 4 (0.14) 0.6284
14 R509 Fever, unspecified 5 (0.13) 0 (0.0) 5 (0.18) 0.5947
15 T813 Disruption of operation wound, not elsewhere classified 5 (0.13) 0 (0.0) 5 (0.18) 0.5947
16 N359 Urethral stricture, unspecified 4 (0.11) 2 (0.21) 2 (0.07) 0.2363
17 R074 Chest pain, unspecified 4 (0.11) 1 (0.11) 3 (0.11) 1.0000
18 Othersb 97 (2.62) 18 (1.91) 79 (2.86) 0.2811
aFishers exact test.
bTotal number of cases <4.
Table 6. Comparison between open and robot-assisted surgery concerning
complications.
RRPa RALPb
Variable (n¼ 942) (n¼ 2764) p-valuec
Clavien-Dindo grade
I 3 (0.3) 40 (1.4) <0.001
II 155 (16.5) 187 (6.8)
IIIa 25 (2.7) 37 (1.3)
IIIb 18 (1.9) 42 (1.5)
IV 0 4 (0.14)
aRetro pubic radical prostatectomy.
bRobot assisted laparoscopic radical prostatectomy.
cChi2-test of independence.
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retropubic radical prostatectomy, respectively [29]. In this
study, we studied the same outcome using healthcare
reported outcomes this time, as generated by The National
Inpatient Registry. Contrary to that notion, in the SPCG-7
randomized trial comparing radiation to hormonal depriv-
ation, Steinsvik et al. [30] have reported that physicians may
over-report complications compared to the actual suffering
patients. On the other hand, Litwin et al. [31] have suggested
that patients reported more complications, as seen in the
CaPSURE study. In our study, there was agreement between
patients and healthcare professionals. This could be attrib-
uted to LAPPROs designs and strengths. We could hypothe-
size that patient-reported outcomes might offer a high-
quality dataset, from which important and accurate conclu-
sions could be drawn, when care is taken for data gathering
standardized reporting.
The strengths in our study include the prospective con-
trolled design, size, short inclusion period, high response
rate, use of validated measures and the neutral third-party
approach [32]. We made sure to obtain accurate information
of known and suspected risk factors for adjustment. The sys-
tematic classification of complications using a widely
adopted instrument revealed important differences between
surgical techniques concerning the post-operative course in
comparison with patient-reported data. One limitation in the
original dataset was that readmissions as reported by health-
care professionals in C.R.F.s probably were limited to that
particular hospital. A certain proportion of the participants
were operated on not at the neighboring hospital, but
referred to a more distant one. Thus, readmissions could
have been missed. To counteract this possible limitation that
could theoretically have been skewed regarding type of sur-
gical technique, we choose to retrieve information from the
National Inpatient Registry, where all hospitals by law must
report data on all inpatient care episodes.
Conclusion
There is a substantial risk for re-admittance after radical pros-
tatectomy, regardless of surgical technique. Complications
are in most cases of low-to-moderate severity. Severe compli-
cations are rare for both open and robotic prostatectomy,
but differ in types.
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